Intervention
Cetrelimab
ClinicalTrials.gov intervention label
Clinical trials
6 shownA Study of Tolododekin Alfa (ANK-101) in Combination With an Anti-PD-1/PD-L1 Antibody in Participants With Advanced Non-Small Cell Lung CancerNCT07027514 · 2025-10-22
RECRUITINGA Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate CancerNCT05818683 · 2023-04-26
RECRUITINGA Study of JNJ-86974680 in Participants With Advanced Non-small Cell Lung CancerNCT06116786 · 2023-11-27
ACTIVE_NOT_RECRUITINGA Study of Combination Therapy With Amivantamab and Cetrelimab in Participants With Metastatic Non-small Cell Lung CancerNCT05908734 · 2023-05-18
ACTIVE_NOT_RECRUITINGApalutamide Plus Cetrelimab in Patients With Treatment-Emergent Small Cell Neuroendocrine Prostate CancerNCT04926181 · 2022-03-16
TERMINATEDCabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate CancerNCT04592237 · 2020-12-29
ACTIVE_NOT_RECRUITINGCommon conditions
Carcinoma, Non-small-Cell Lung2Aggressive Variant Prostate Carcinoma1Castration-Resistant Prostate Carcinoma1Metastatic Castration-resistant Prostate Neoplasms1Metastatic Hormone-sensitive Prostate Cancer1Metastatic Prostate Carcinoma1Metastatic Prostate Neuroendocrine Carcinoma1Metastatic Prostate Small Cell Carcinoma1Non Small Cell Lung Cancer1Prostate Cancer1Small Cell Carcinoma1Small Cell Neuroendocrine Carcinoma1Stage IV Prostate Cancer AJCC v81
Leading sponsors
Trial status mix
ACTIVE_NOT_RECRUITING3
RECRUITING2
TERMINATED1
Phase mix
PHASE14
PHASE23
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.